A Randomized, Phase 3, Open-label Study of Neoadjuvant Darovasertib in Subjects with Primary Non-metastatic Uveal Melanoma (OptimUM-10)
Phase: Phase III clinical trials
Principal Investigator: Dott.ssa Angi Martina
Main Facility: Struttura Complessa Chirurgia Generale 4 – Chirurgia del Melanoma e dei Tumori Oculari
Drug: Darovasertib
Pathologies: Melanoma
The drug darovasertib will be evaluated in the neoadjuvant setting in patients with primary, non-metastatic uveal melanoma (UM) requiring plaque brachytherapy (PB) or enucleation. For the patient population eligible for PB (Cohort 1), it is hypothesized that, compared to immediate PB, darovasertib reduces tumor size and the radiation dose delivered via PB. For the patient population eligible for enucleation (Cohort 2), it is hypothesized that the drug reduces tumor size, thereby decreasing the need for enucleation as the primary treatment.
Last update: 06/10/2026